Cell therapy

Cell engineering
#Cell therapy #Engineered cells #Immusoft #Phase I trial #Rare disease

World’s first engineered B cell therapy enters human trials

The first patient has been dosed with an engineered B cell investigational therapy in a Phase I trial in Mucopolysaccharidosis type I (MPS I). Developer Immusoft has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for the therapy, designated ISP-001, in this indication. Read More

#Editor's Choice #News

Multiple myeloma
#Bristol Myers Squibb #CAR-T #Cell therapy #Immunotherapy #Japan #Myeloma

First CAR-T therapy approved for earlier use in treatment of myeloma

Bristol-Myers Squibb has received manufacturing and marketing approval in Japan for Abecma (idecabtagene vicleucel) as a third-line therapy for relapsed or refractory multiple myeloma (RRMM). Abecma is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy. It is now approved for RRMM patients who have received at… Read More

#News #Regulatory

Natural killer cells
#Bispecific Antibodies #Cell therapy #Collaboration #NAYA Biosciences #Oncology #ONK Therapeutics

Partners explore NK cell therapy and bispecific antibodies combo

ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. The partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted… Read More

#Business & Investment #Cancer Research #News

#Alzheimer's #Cancer research #Cell therapy #CRISPR #Drug discovery #Parkinson's #Plant-based #Stem cells

New DDW Highlights podcast: 4 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The key drug discovery news this week focuses on experimental approaches to… Read More

#News

#Alzheimer's #Cancer research #Cell therapy #CRISPR #Drug discovery #Parkinson's #Plant-based #Stem cells

This week in drug discovery (27 Nov – 1 Dec) 

News round-up for 27 November – 1 December by DDW Digital Content Editor Diana Spencer. The key drug discovery news this week focuses on experimental approaches to the treatment of some of the most challenging diseases, including a mathematical model that can simulate Alzheimer’s progression and… Read More

#News

FDA headquarters
#Adverse event #Blood cancer #CAR-T #Cell therapy #FDA #Immunotherapy #Oncology

FDA investigates safety of CAR-T cell immunotherapies

The Food and Drug Administration (FDA) said it will investigate the safety of BCMA- or CD19-directed autologous CAR-T cell immunotherapies, following reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in these patients. The reports were received from clinical trials and postmarketing adverse event (AE) data sources. Despite… Read More

#News #Regulatory #Trending News

Embryonic stem cells
#Cell therapy #Multiple sclerosis #Stem cells #University of Cambridge #University of Colorado #University of Milano-Bicocca

Stem cell therapy shows promise in advanced MS

An international team of scientists has shown that a stem cell therapy for multiple sclerosis (MS) could prevent further damage to the brain. The early-stage clinical trial was the result of a collaboration between researchers at University of Colorado Anschutz Campus, the University of Cambridge and… Read More

#News #Trending News

#Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

DDW eBook: The latest innovations in cell and gene therapy

Hailed as a revolution in the treatment of many diseases, cell and gene therapy is the fastest growing area of therapeutics. This eBook, ‘Cell & Gene Therapy: The advances and innovation’, provides a comprehensive overview of the latest innovations in cell and gene therapies, where the… Read More

#News

#Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

Cell & Gene Therapy: The advances and innovation

This 24-page eBook sponsored by Sartorius explores the latest innovations in cell and gene therapies, where the challenges lie and the possible solutions to overcoming these obstacles. Download this free resource to learn more about: The ways cell and gene therapies (CGTs) are revolutionising medicine in a range of diseases How… Read More

#DDW eBooks #Intelligence

#CAR-T #Cell and gene therapy #Cell therapy #CRISPR #Drug discovery #Gene therapy

New DDW Highlights podcast: 20 November 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The breaking news this week was certainly the first regulatory approval for… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #CRISPR #Drug discovery #Gene therapy

This week in drug discovery (13-17 November) 

News round-up for 13-17 November by DDW Digital Content Editor Diana Spencer. The breaking news this week was certainly the first regulatory approval for Casgevy, not only the first gene therapy approved for sickle cell disease, but also the first therapy to use CRISPR gene editing. Read More

#News

Multiple myeloma
#Arcellx #CAR-T #Cell therapy #Clinical trial #Haematology #Myeloma #Oncology #Phase I trial

CART-ddBCMA trial shows durable response in myeloma patients

Arcellx has revealed encouraging interim data from its Phase I study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The company plans to present new data with a median follow-up of 26.5 months at the 65th American Society of Hematology (ASH) Annual Meeting and… Read More

#Cancer Research #News

CAR-T therapy
#Cancer research #CAR-T #Cell therapy #EMA #Kite Pharma #Oncology #Phase III trial

CAR-T therapy Yescarta reduces risk of death by more than 27%

New trial evidence has shown that Kite’s CAR-T cell therapy Yescarta (axicabtagene ciloleucel: axi-cel) reduces the risk of death by 27.4% in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), corresponding to a 38% improvement in overall survival (OS). It is the only treatment in nearly 30 years… Read More

#Cancer Research #News #Regulatory

#Antibody drug conjugate (ADC) #Cell therapy #Drug discovery #Immunology / Virology & Vaccines #Phase I trial

New DDW Highlights podcast: 30 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news highlights this week feature a variety of treatment approaches, from… Read More

#News

#Antibody drug conjugate (ADC) #Cell therapy #Drug discovery #Immunology / Virology & Vaccines #Phase I trial

This week in drug discovery (23-27 October)  

News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer. My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of… Read More

#News

Flow cytometry
#Cell line development #Cell therapy #Drug development #Drug discovery #Flow Cytometry #Guide

Don’t miss out on the easier way to do flow cytometry

Download the ‘Advanced Flow Cytometry Handbook‘ to discover the easier way to do flow cytometry. In this new handbook, Sartorius introduces the value of advanced flow cytometry, to ensure that every scientist feels empowered to run an experiment and analyse the data with confidence. This easy-to-use digital… Read More

#News